Platelet contributions to the pathogenesis of systemic sclerosis
- PMID: 17917538
- DOI: 10.1097/BOR.0b013e3282eeb3a4
Platelet contributions to the pathogenesis of systemic sclerosis
Abstract
Purpose of review: The purpose of this review is to focus attention on platelet contributions, in general, to systemic sclerosis. There have also been recent advances in characterization of the phenotype of platelets in systemic sclerosis which will be reviewed.
Recent findings: An extensive literature provides strong support for varying degrees of platelet activation and aggregation in different forms and stages of systemic sclerosis. A recent finding is that systemic sclerosis platelets overexpress a specific nonintegrin 65 kDa receptor for type I collagen as well as expressing enhanced phosphilidylinositol-3 kinase as an activation signature. Overexpression of a type I collagen receptor would make systemic sclerosis platelets more susceptible to binding to exposed type I collagen in the subendothelial lining of damaged blood vessels, facilitating the cycle of platelet aggregation and release of preformed bioactive molecules that include a host of inflammatory and fibrogenic, chemokines, cytokines and growth factors. This activation phenotype of systemic sclerosis platelets may be secondary to autoimmunity and driven by cytokines from autoreactive T cells.
Summary: The contributions of platelets to the pathogenesis of systemic sclerosis is likely substantial and may not be adequately represented in gene profiling of systemic sclerosis tissue due to the small amounts of RNA contained in platelets.
Similar articles
-
Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis.Thromb Res. 2006;117(3):299-306. doi: 10.1016/j.thromres.2005.03.003. Thromb Res. 2006. PMID: 16378833
-
The immunobiology of systemic sclerosis.Semin Arthritis Rheum. 2008 Oct;38(2):132-60. doi: 10.1016/j.semarthrit.2007.10.010. Epub 2008 Jan 25. Semin Arthritis Rheum. 2008. PMID: 18221988 Review.
-
Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.Autoimmun Rev. 2007 Dec;7(2):121-6. doi: 10.1016/j.autrev.2007.02.020. Epub 2007 Mar 28. Autoimmun Rev. 2007. PMID: 18035321 Review.
-
Update on autoantibodies in systemic sclerosis.Curr Opin Rheumatol. 2007 Nov;19(6):580-91. doi: 10.1097/BOR.0b013e3282e7d8f9. Curr Opin Rheumatol. 2007. PMID: 17917539
-
Molecular pathways as novel therapeutic targets in systemic sclerosis.Curr Opin Rheumatol. 2007 Nov;19(6):568-73. doi: 10.1097/BOR.0b013e3282e6f495. Curr Opin Rheumatol. 2007. PMID: 17917537 Review.
Cited by
-
Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!J Scleroderma Relat Disord. 2020 Feb;5(1):6-20. doi: 10.1177/2397198319857356. Epub 2019 Jun 28. J Scleroderma Relat Disord. 2020. PMID: 35382401 Free PMC article. Review.
-
Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue diseases).J Nephrol. 2021 Aug;34(4):1069-1080. doi: 10.1007/s40620-020-00772-7. Epub 2020 Jun 11. J Nephrol. 2021. PMID: 32529559 Review.
-
Inhibition of angiogenesis by platelets in systemic sclerosis patients.Arthritis Res Ther. 2015 Nov 19;17:332. doi: 10.1186/s13075-015-0848-2. Arthritis Res Ther. 2015. PMID: 26584613 Free PMC article.
-
The role of platelets in the pathogenesis of systemic sclerosis.Front Immunol. 2012 Jun 18;3:160. doi: 10.3389/fimmu.2012.00160. eCollection 2012. Front Immunol. 2012. PMID: 22719739 Free PMC article.
-
From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders.Rheumatol Int. 2018 Jun;38(6):959-974. doi: 10.1007/s00296-018-4001-9. Epub 2018 Feb 28. Rheumatol Int. 2018. PMID: 29492586 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials